<ul data-eligibleForWebStory="true"><li>64x Bio has unveiled the AAV Apex Suite for scalable gene therapy manufacturing at BIO 2025 in Boston.</li><li>The AAV Apex Suite includes suspension-adapted HEK293 cell lines and production protocols delivering high-yield AAV production.</li><li>Key features of the suite include suspension-friendly HEK293 cells, tailored production protocols, cross-serotype consistency, and compatibility with existing bioreactors.</li><li>The platform addresses manufacturing bottlenecks in gene therapy by offering a turnkey solution supporting high-volume production, with plans for public performance benchmarks and early-access collaborations.</li></ul>

# 64x Bio Unveils AAV Apex Suite for Scalable Gene Therapy Manufacturing

Discover more